Nordic Nanovector launches US Phase 2b trial for Betalutin in follicular lymphoma

Nordic Nanovector, a Norwegian biopharmaceutical company, has commenced the first clinical site in the United States for its PARADIGME trial. This pivotal trial is designed ... Read More